Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Artfinder is the art world's first certified B corporation that is on a mission to create a world where art benefits everyone. Operating in the $55 billion+ wall décor and online art market, the company is backed by Wellington Partners, and private investors in the UK, US and Switzerland. It has 60,000 customers, 6,000 artists and a collection of 470,000 artworks. The company believes in establishing direct contact with artists to select or commission work and negotiate prices. Customers have rated the company highly with 4.8+ Trustpilot reviews. The company will use the investment to supercharge its growth, grow its team and improve its platform.
days to go:
Expired
investment:
£834,056
Clooper is a property management platform. The company argues that 86% of private landlords in the UK manage their properties themselves, with many finding it time-consuming and stressful. Clooper seeks to solve this problem with a property management platform that connects landlords, tenants, trade services, and homeowners to facilitate easy transactions between them. It aims to be a significant contender in the £11 billion property management platform. The company points out that Paul Rothwell of Empire, a large residential landlord in England, has pledged £200,000 of investment to the company. Clooper aims to make move-ins quicker, repairs faster, and payments easier in the wake of Covid-19 which is fuelling the adoption of online services in the UK. The company will use the investment to hire key recruits, operationalise mobile apps, boost marketing, and enhance sales and operations.
days to go:
Expired
investment:
£409,847
Biohm is an eco-conscious bio-technology company that is revolutionising construction through nature-inspired innovation. The company has adopted methods such as circular construction system, biomimicry, and triagomy. Some of the company’s carbon-negative bio-based materials include building insulation made out of Mycelium (the root structure of mushrooms) and ORB (Organic Refuse Biocompound), a 100% natural sheet material made out of food and agricultural surplus. For its innovation, Biohm won the Waitrose and Partners Plan Plastic Prize: The Million Pound Challenge and a Power to Change grant worth £600,000 to build sustainable living premises. It has also been shortlisted as one of The United Nation’s ‘Young Champions of the Earth’. The company will use 38% of the investment to grow its team, 22% to scale Research and Development (R&D), 22% to protect its Intellectual Property (IP), and 18% for product accreditation.
days to go:
Expired
investment:
£790,700
Active Needle Technology offers an award-winning "needle actuating device" which has high value medical and consumer applications. The company's patent-pending proprietary ultrasonic technology enhances visibility for medical needles in applications such as biopsy, in regional and joint anaesthesia and others. The company aims to commercialise its technology into a $4+ billion special purpose needle market. After identifying obvious commercial advantages in the tattoo market, Active Needle plans to use its ultrasonic needle technology to develop a low-pain tattooing system. Moreover, the company has won an Innovate UK grant to develop and test the tattoo device. With the proceeds, the company will complete CE marking for its initial biopsy device, for development of anaesthesia and tattooing products.
days to go:
Expired
investment:
£194,100
Plug-N-Go is a company that provides electric vehicle charging infrastructure with the aim of sustainably electrifying transport. The company has 24 charge points that are accessible to users via its app. It sources 100% renewable energy from its partners at Octopus Energy. Air pollution is contributing to 40,000 early deaths a year in the UK that Plug-N-Go is striving to change. The global electric vehicle charging stations market will reach USD 27.7 billion by 2027 from an estimated USD 2.5 billion in 2019. The company hopes to become a strong contender in this segment. Plug-N-Go is in discussions over multi-site agreements with the Co-operative Society and Eden district council and has received interest from Associated British Ports. Its goal is to install 3,800 EV charge points for the public in 5 years at sites where drivers are already parking. The company will use the investment to deliver EV charging stations to businesses across the UK.
days to go:
Expired
investment:
£176,008
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£326,190
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.
days to go:
Expired
investment:
£1,036,436
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.
days to go:
Expired
investment:
£134,892
Advanced Blast & Ballistic Systems (ABBS) is a company that has developed globally patented systems to counteract the forces an armoured vehicle sustains when a mine or Improvised Explosive Device (IED) explodes under it. As per reports, mines and IEDs accounted for over 80% of UK and US army casualties in Iraq & Afghanistan. ABBS believes that its products can keep occupants inside a vehicle completely safe from the aforementioned explosive devices. The armoured vehicle protection market has a value of about $20 billion wherein ABBS aims to be a major contender. The company has received £2 million-plus revenues till date from Research and Development (R&D) grants in the UK, as well as, sold its products to the US Army and Israel with profits worth £145,000 in 2018 and £560,000 in 2019 respectively. It will use the investment to bring its products to more markets globally.
days to go:
Expired
investment:
£445,814
